Antibody-drug conjugate

This page covers all Antibody-drug conjugate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Receptor tyrosine-protein kinase erbB-2, Tissue factor, human epidermal growth factor receptor 2 (HER2).

Targets

Receptor tyrosine-protein kinase erbB-2 · Tissue factor · human epidermal growth factor receptor 2 (HER2) · Trop-2 · VEGFA, HER2 · CD30 · FGFR3

Marketed (3)

• Kadcyla · Roche · Oncology · 900
  Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent.
• Tivdak · SEAGEN · Oncology · 147
  Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells.
• Disitamab vedotin · Pfizer · Oncology

Phase 3 pipeline (1)

• Rescue medications for sacituzumab tirumotecan · Merck Sharp & Dohme LLC · Oncology
  Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2, delivering a cytotoxic payload to cancer cells.

Phase 2 pipeline (3)

• Bevacizumab and trastuzumab maintenance therapy · Sanofi · Oncology
  Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2)
• Antibody-Drug Conjugates · Hellenic Cooperative Oncology Group · Oncology
  Targeting CD30
• Antibody-Drug Conjugate · Sung-Soo Park · Oncology
  Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell.

Phase 1 pipeline (1)

• AMG 410 · Amgen · Oncology
  Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3)